Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

Table 3 Effect of panitumumab in phase III studies in patients with metastatic colorectal cancer

Study	Treatment	Phase	Regimen	Patients (n)	Overall response	Median PFS (mo)	Median OS (mo)
Van Cutsem et al[33],	Refractory to standard CTX	3	Panitumumab + BSC	231	10%
2007			vs
			BSC	232	0%	HR = 0.54	HR = 1.0
					P < 0.0001
Douillard et al[34],	First-line	3	K-Ras WT
PRIME-trial,			FOLFOX4 + panitumumab	325	55%	9.6	23.9
2010			FOLFOX4	331	48%	8.0	19.7
					OR = 1.35	HR = 0.8	HR = 0.83
					P = 0.068	P = 0.02	P = 0.072
			K-Ras MT
			FOLFOX4 + panitumumab	221	40%	7.3	15.5
			FOLFOX	219	40%	8.8	19.3
						HR = 1.29	HR = 1.24
						P = 0.02	P = 0.068
Peeters et al[35],	Second-line	3	K-Ras WT
2010			FOLFIRI + panitumumab	303	35%	5.9	14.5
			FOLFIRI	294	10%	3.9	12.5
					P = 0.001	HR = 0.73	HR = 0.85
						P = 0.004	P = 0.12
			K-Ras MT
			FOLFIRI + panitumumab	238	13%	5.0	11.8
			FOLFIRI	248	14%	4.9	11.1
						HR = 0.85	HR = 0.94
						P = 0.14
Douillard et al[36],	First-line	3	K-Ras WT/MT other Ras
Update			FOLFOX4 + panitumumab	51	NR	7.3	17.1
Prime-trial,			FOLFOX4	57	NR	8.0	18.3
2013						HR = 1.28	HR = 1.29
						P = 0.326	P = 0.305
			K-Ras + N-Ras WT
			FOLFOX4 + panitumumab	259	NR	10.1	26.0
			FOLFOX	253	NR	7.9	20.2
						HR = 0.72	HR = 0.78
						P = 0.004	P = 0.043
Schwartzberg et al[37],	First-line	2	K-Ras WT/MT other RAS				Not
PEAK-trial,			mFOLFOX6 + panitumumab	142	NR	10.9	Reached
2013			mFOLFOX6 + bevacizumab	143	NR	10.1	25.4
						HR = 0.87	HR = 0.72
						P = 0.35	P = 0.14
			K-Ras / N-RAS WT				Not
			mFOLFOX6 + panitumumab mFOLFOX6 + bevacizumab	88	NR	13.0	Reached
				82	NR	9.5	29.0
						HR = 0.65	HR = 0.61
						P = 0.03	P = 0.09

PFS: Progression free survival; OS: Overall survival; BSC: Best supportive care; CTX: Chemotherapy; WT: Wild-type; MT: Mutant; NR: Not reported.